There is only one Cardiolite

Imaging Protocols

Several protocols have been developed for myocardial perfusion imaging with Cardiolite®. Depending on your lab and the needs of your patients, these protocols describe the studies to be performed in one day or over two days.1,2

One-Day Study
  • Schedule your patients to complete testing in one day (5–8 hours)
  • Perform rest/stress or stress/rest protocols
  • Results are comparable between one-day protocols
Two-Day Study
  • Shorter appointments over two days (1–2 hours each day)
  • Normal stress scan in patients with low likelihood of CAD may reduce need for rest portion
  • Perform stress/rest protocols
Contact your Lantheus Medical Imaging representative for more information
Click here to view footnotes
  1. Henzlova MJ, Duvall WL, Einstein AJ, et al. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol. 2016;23(3):606-39.
  2. Cardiolite® [package insert]. N. Billerica, MA: Lantheus Medical Imaging.

 

INDICATIONS AND USAGE FOR CARDIOLITE®:
Myocardial Imaging:  Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions.  Cardiolite® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g. exercise or pharmacologic stress in accordance with the pharmacologic stress agent’s labeling).

CONTRAINDICATIONS:
None known.

IMPORTANT SAFETY INFORMATION: 
Cardiolite® has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria.  In some patients the allergic symptoms developed on the second injection during Cardiolite® imaging.  The most frequently reported adverse events include headache, chest pain/angina, ST segment changes on ECG, nausea, and abnormal taste and smell.

Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing (See Section 5.2). Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction and cerebrovascular events.

WARNINGS AND PRECAUTIONS:
In studying patients in whom cardiac disease is known or suspected, care should be taken to assure continuous monitoring and treatment in accordance with safe, accepted clinical procedure.

Caution should be exercised and emergency equipment should be available when administering Cardiolite®.

Before administering Cardiolite® patients should be asked about the possibility of allergic reactions to either Cardiolite® or Miraluma®. Miraluma® is an identical compound used in breast imaging.

The contents of the vial are intended only for use in the preparation of Technetium Tc99m Sestamibi and are not to be administered directly to the patient without first undergoing the preparative procedure.

Please see full Prescribing Information: Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)

 

Scroll up to site navigation

 

Lantheus Medical Imaging

This site is intended for U.S. Residents.
Cardiolite®, Lantheus Medical Imaging and the corporate logo are
registered trademarks of Lantheus Medical Imaging, Inc.
Use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.
© 2020 Lantheus Medical Imaging, Inc. All Rights Reserved.